CD33 and myelodysplastic syndrome: Notably, MDSCs were reported to be significantly increased in MDS BM (Figure 2) and transgenic MDS mouse models, are distinct from the neoplastic clone and associated with impaired haematopoiesis through a mechanism driven, at least in part, by the interaction of S100A9 with an endogenous ligand for CD33-initiated signalling [140,141,142].